- Home
- TERN vs MIRM Comparison
TERN vs MIRM Comparison
Compare TERN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TERN | MIRM |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.2B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TERN | MIRM |
|---|---|---|
| Price | $34.33 | $103.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 11 |
| Target Price | $48.60 | ★ $100.09 |
| AVG Volume (30 Days) | ★ 2.1M | 809.9K |
| Earning Date | 03-19-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $471,794,000.00 |
| Revenue This Year | N/A | $54.98 |
| Revenue Next Year | N/A | $21.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 53.66 |
| 52 Week Low | $1.87 | $36.88 |
| 52 Week High | $48.26 | $101.50 |
Technical Indicators
Market Signals| Indicator | TERN | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 80.66 |
| Support Level | $33.60 | $89.47 |
| Resistance Level | $35.46 | $93.70 |
| Average True Range (ATR) | 1.93 | 4.20 |
| MACD | -0.56 | 0.94 |
| Stochastic Oscillator | 18.52 | 99.71 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.